Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, reports the vesting and subsequent tax withholding related to restricted stock units.
Summary
- On February 14, 2025, Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, had 9,667 restricted stock units vest.
- These units convert into common stock.
- The company withheld 2,353 shares to cover withholding taxes.
- Following these transactions, Elsbernd directly owns 188,564 shares of Catalyst Pharmaceuticals common stock and 1,071,609 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock vesting and tax withholding, with no inherent positive or negative implications for the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may monitor insider transactions for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| February 14, 2023 | 1/3rd of restricted stock units vested |
| February 14, 2024 | 1/3rd of restricted stock units vested |
| February 14, 2025 | Final 1/3rd of restricted stock units vested; shares delivered within 60 days |
| February 19, 2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.